P2X7 receptor mediates the anti-tumor effect of running on cervical cancer in mice.

IF 2.5 4区医学 Q2 NEUROSCIENCES

Purinergic Signalling Pub Date : 2026-04-15 DOI:10.1007/s11302-026-10143-9

Hai-Yun Xiong, Rui Li, Xiu-Min Hu, Yi Zhang, Patrizia Rubini, Peter Illes, Yong Tang

{"title":"P2X7 receptor mediates the anti-tumor effect of running on cervical cancer in mice.","authors":"Hai-Yun Xiong, Rui Li, Xiu-Min Hu, Yi Zhang, Patrizia Rubini, Peter Illes, Yong Tang","doi":"10.1007/s11302-026-10143-9","DOIUrl":null,"url":null,"abstract":"<p><p>Previous studies have suggested that running exerts anti-tumor effects on various cancers through multiple pathways. It has been reported that the P2X7 receptor (P2X7R) may display anti-tumor activity in cervical cancer cells, and running can regulate P2X7R expression and function in mice. However, the specific impact of running on cervical cancer and whether its underlying mechanism is associated with the regulation of P2X7R levels remains to be elucidated. In this study, mice bearing U14 cervical cancer tumors were used as a model to explore the association between running and P2X7R in cervical cancer. The results showed that running significantly inhibited tumor progression in mice, accompanied by an increase in P2X7R protein expression in tumor tissues. Additionally, treatment with the P2X7R antagonist JNJ-47965567 alone or in combination with running intervention promoted tumor growth and attenuated the anti-tumor effect of running. In contrast, the P2X7R agonist BzATP alone or combined with running intervention exerted anti-tumor effects and enhanced the anti-tumor effect of running. In conclusion, the present findings suggest only a pharmacological association between P2X7R and the anti-tumor effect of running against cervical cancer progression, given that genetic validation was not performed in this study. The potential involvement of immune mechanisms remains an inference and requires further experimental validation. As a possible therapeutic target, P2X7R provides supportive data for the treatment of cervical cancer and the clinical exploration of running as an adjuvant intervention.</p>","PeriodicalId":20952,"journal":{"name":"Purinergic Signalling","volume":"22 2","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13083685/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Purinergic Signalling","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11302-026-10143-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Previous studies have suggested that running exerts anti-tumor effects on various cancers through multiple pathways. It has been reported that the P2X7 receptor (P2X7R) may display anti-tumor activity in cervical cancer cells, and running can regulate P2X7R expression and function in mice. However, the specific impact of running on cervical cancer and whether its underlying mechanism is associated with the regulation of P2X7R levels remains to be elucidated. In this study, mice bearing U14 cervical cancer tumors were used as a model to explore the association between running and P2X7R in cervical cancer. The results showed that running significantly inhibited tumor progression in mice, accompanied by an increase in P2X7R protein expression in tumor tissues. Additionally, treatment with the P2X7R antagonist JNJ-47965567 alone or in combination with running intervention promoted tumor growth and attenuated the anti-tumor effect of running. In contrast, the P2X7R agonist BzATP alone or combined with running intervention exerted anti-tumor effects and enhanced the anti-tumor effect of running. In conclusion, the present findings suggest only a pharmacological association between P2X7R and the anti-tumor effect of running against cervical cancer progression, given that genetic validation was not performed in this study. The potential involvement of immune mechanisms remains an inference and requires further experimental validation. As a possible therapeutic target, P2X7R provides supportive data for the treatment of cervical cancer and the clinical exploration of running as an adjuvant intervention.

查看原文本刊更多论文

P2X7受体介导跑步对小鼠宫颈癌的抗肿瘤作用。

先前的研究表明，跑步通过多种途径对多种癌症发挥抗肿瘤作用。有报道称，P2X7受体（P2X7R）可能在宫颈癌细胞中表现出抗肿瘤活性，跑步可调节小鼠P2X7R的表达和功能。然而，跑步对宫颈癌的具体影响及其潜在机制是否与P2X7R水平的调控有关仍有待阐明。本研究以携带U14宫颈癌肿瘤的小鼠为模型，探讨跑步与P2X7R在宫颈癌中的关系。结果显示，跑步显著抑制小鼠肿瘤进展，肿瘤组织中P2X7R蛋白表达增加。此外，P2X7R拮抗剂JNJ-47965567单独或联合跑步干预可促进肿瘤生长，减弱跑步的抗肿瘤作用。相比之下，P2X7R激动剂BzATP单独或联合跑步干预发挥抗肿瘤作用，增强了跑步的抗肿瘤作用。综上所述，鉴于本研究未进行基因验证，本研究结果表明P2X7R与跑步抗宫颈癌进展的抗肿瘤作用之间仅存在药理学关联。免疫机制的潜在参与仍然是一个推论，需要进一步的实验验证。P2X7R作为一种可能的治疗靶点，为宫颈癌的治疗和临床探索跑步作为辅助干预手段提供了支持性数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Purinergic Signalling 医学-神经科学

CiteScore

6.60

自引率

17.10%

发文量

审稿时长

6-12 weeks

期刊介绍： Nucleotides and nucleosides are primitive biological molecules that were utilized early in evolution both as intracellular energy sources and as extracellular signalling molecules. ATP was first identified as a neurotransmitter and later as a co-transmitter with all the established neurotransmitters in both peripheral and central nervous systems. Four subtypes of P1 (adenosine) receptors, 7 subtypes of P2X ion channel receptors and 8 subtypes of P2Y G protein-coupled receptors have currently been identified. Since P2 receptors were first cloned in the early 1990’s, there is clear evidence for the widespread distribution of both P1 and P2 receptor subtypes in neuronal and non-neuronal cells, including glial, immune, bone, muscle, endothelial, epithelial and endocrine cells.